← All trials
NCT05299203
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- May 31, 2023
- First posted
- Mar 28, 2022
- Last posted
- Mar 28, 2022
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan UniversityLead sponsor
- Sichuan UniversityOverall official - principal investigator
- Sichuan UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.